Your browser doesn't support javascript.
loading
Compliance to Viral Load Monitoring Schedules Among Women Attending Prevention of Vertical HIV Transmission Services Before and During the COVID-19 Pandemic in Ehlanzeni District, Mpumalanga, South Africa.
Mbira, Thandiwe Elsie; Kufa, Tendesayi; Sherman, Gayle Gillian; Ngandu, Nobubelo Kwanele.
Affiliation
  • Mbira TE; HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa.
  • Kufa T; Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
  • Sherman GG; Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
  • Ngandu NK; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.
AIDS Behav ; 28(3): 868-885, 2024 Mar.
Article in En | MEDLINE | ID: mdl-37831233
Human immunodeficiency virus (HIV) viral load (VL) monitoring was likely interrupted during the Coronavirus disease 2019 (COVID-19) pandemic. We used routine data on repeat VL testing among 667 prevention of vertical HIV transmission (PVT) clients in Ehlanzeni district, to determine compliance to VL testing recommendations and associated factors during different time periods: pre-COVID-19, transition, and COVID-19. Descriptive and multivariable Poisson regression analyses were conducted, with and without including revised PVT-guidelines rolled out in January-2020. Among 405 women with ≥ 2 VL tests, the overall median age was 30 years (interquartile range: 26-35 years). Compliance to recommended VL testing guidelines ranged between 81.5% (172/211) and 92.3% (191/207) at different time periods. Across all three periods and when revised PVT-guidelines were used, being compliant was significantly reduced among those with earliest VL = 50-999 copies/ml (incidence rate ratio (IRR) = 0.71 [95% confidence interval (CI) 0.61-0.82], p value < 0.001) and VL ≥ 1000 copies/ml (IRR = 0.18 [95% CI 0.09-0.36], p value < 0.001). When guideline revisions were excluded, compliance was only significantly reduced among those with VL ≥ 1000 copies/ml (IRR = 0.14 [95% CI 0.06-0.32], p value < 0.001) and increased during the COVID-19 period versus pre-COVID-19 (IRR = 1.10 [95% CI 1.05-1.15], p value < 0.001). Similar significant associations between compliance and VL level were observed when the COVID-19 period was analyzed separately. Significantly increased compliance to VL testing among the 25-34 years age-group versus younger women was also observed across all periods. These results highlight the importance of strengthening strategies such as short message service reminders and educational messaging, reaching all age-groups, to fast-track implementation targets for VL monitoring.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / COVID-19 Limits: Adult / Female / Humans Country/Region as subject: Africa Language: En Journal: AIDS Behav Journal subject: CIENCIAS DO COMPORTAMENTO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2024 Type: Article Affiliation country: South Africa

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / COVID-19 Limits: Adult / Female / Humans Country/Region as subject: Africa Language: En Journal: AIDS Behav Journal subject: CIENCIAS DO COMPORTAMENTO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2024 Type: Article Affiliation country: South Africa